NCT01701830

Brief Summary

The aim of the study is to evaluate whether a low level of serum omentin-1 is associated with carotid atherosclerosis and mediated by inflammation.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
85

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Oct 2012

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2012

Completed
2 days until next milestone

First Submitted

Initial submission to the registry

October 3, 2012

Completed
2 days until next milestone

First Posted

Study publicly available on registry

October 5, 2012

Completed
7 months until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2013

Completed
Last Updated

October 5, 2012

Status Verified

October 1, 2012

First QC Date

October 3, 2012

Last Update Submit

October 4, 2012

Conditions

Non-diabetic Chronic Kidney DiseaseAtherosclerosis

Keywords

omentin-1carotid atherosclerosiskidney disease

Study Arms (2)

Case Group

Patients with chronic kidney disease of stage 3-4.

Control group

30 healthy subject

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Department of Nephrology, Check-up clinic

You may qualify if:

  • between ages of 18 - 65 years old chronic kidney disease of stage 3-4

You may not qualify if:

  • Chronic kidney disease of stage 5
  • The history of ischemic cardiovascular disease (myocardial infarction, unstable angina, stroke, peripheral artery disease, or cardiovascular revascularization)
  • Severe heart failure
  • Stage 2 hypertension
  • Diabetes mellitus
  • Corticosteroid therapy
  • Severe hepatic disease
  • Smoking
  • Inflammatory disease
  • Acute infectious disease
  • Malignancy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Department of Nephrology, Check-up Clinic,Kocaeli Derince Education and Traning Hospital

İzmit, Kocaeli, 41100, Turkey (Türkiye)

RECRUITING

MeSH Terms

Conditions

AtherosclerosisCarotid Artery DiseasesKidney Diseases

Condition Hierarchy (Ancestors)

ArteriosclerosisArterial Occlusive DiseasesVascular DiseasesCardiovascular DiseasesCerebrovascular DisordersBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital Diseases

Study Officials

  • Erkan SENGUL, MD

    Kocaeli Derince Education and Training Hospital

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 3, 2012

First Posted

October 5, 2012

Study Start

October 1, 2012

Study Completion

May 1, 2013

Last Updated

October 5, 2012

Record last verified: 2012-10

Locations

TU(1)